Most Recent
The Takeovers Panel has agreed to hear Mayne Pharma's latest dispute with Cosette over the US drug maker's attempts to walk away from their $672 million merger agreement and extended the timeline for completing the deal.
Mayne Pharma has secured an extension of the deadline for securing Foreign Investment Review Board approval of its $672 million tie-up with US drug maker Cosette.
Cosette plans to appeal a ruling that rejected its bid to terminate an agreement to merge with Mayne Pharma, as the US drug company also refuses to agree to conditions needed to win Foreign Investment Review Board approval for the tie-up.
Mayne Pharma has won a dispute with US drug maker Cosette over the termination of a $672 million merger agreement, with a judge finding Mayne did not breach its continuous disclosure obligations by failing to disclose a letter from the US FDA sooner.
Saying the appeals court committed "fundamental errors" in approaching their claim of loss, the applicants in failed cases against the Commonwealth Bank have appealed to the High Court, in a case that could clarity the elusive test for damages in shareholder class actions.
Following the failure of two class actions to prove market-based loss from the Commonwealth Bank’s disclosure breaches, the bank is fighting the class actions' bid to pursue individual ‘no transaction’ cases, saying they were “trying to keep something alive that is truly dead”.
Mayne Pharma and US drug maker Cosette have agreed to postpone the start of trial in a case over the termination of a $672 million merger to allow for late amendments.
Mayne Pharma has denied US drug maker Cosette's claims it breached its continuous disclosure obligations in relation to US FDA concerns about marketing for its Nextstellis contraceptive, as the drug makers spar over their $672 million merger.
A court has heard US drug maker Cosette may amend its case to accuse Adelaide's Mayne Pharma of continuous disclosure breaches in their battle over the termination of their $672 million merger.
With evidence finally in after six years, Lendlease has asked a court to reject a portion of a shareholder class action’s expert reply evidence, arguing it unfairly introduces a new and unforeseen loss methodology.